These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6606179)

  • 1. Surface properties of an amphiphilic peptide hormone and of its analog: corticotropin-releasing factor and sauvagine.
    Lau SH; Rivier J; Vale W; Kaiser ET; Kézdy FJ
    Proc Natl Acad Sci U S A; 1983 Dec; 80(23):7070-4. PubMed ID: 6606179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural homology of corticotropin-releasing factor, sauvagine, and urotensin I: circular dichroism and prediction studies.
    Pallai PV; Mabilia M; Goodman M; Vale W; Rivier J
    Proc Natl Acad Sci U S A; 1983 Nov; 80(22):6770-4. PubMed ID: 6606178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of an amphiphilic peptide with a phospholipid bilayer surface by molecular dynamics simulation study.
    Huang P; Loew GH
    J Biomol Struct Dyn; 1995 Apr; 12(5):937-56. PubMed ID: 7626245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary structure prediction of sauvagine, a novel biologically active polypeptide from a frog.
    Montecucchi PC; Gozzini L
    Int J Pept Protein Res; 1982 Aug; 20(2):139-43. PubMed ID: 6981615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges.
    Koerber SC; Gulyas J; Lahrichi SL; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
    J Med Chem; 1998 Dec; 41(25):5002-11. PubMed ID: 9836618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
    Grigoriadis DE; Liu XJ; Vaughn J; Palmer SF; True CD; Vale WW; Ling N; De Souza EB
    Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain.
    Berger H; Heinrich N; Wietfeld D; Bienert M; Beyermann M
    Br J Pharmacol; 2006 Dec; 149(7):942-7. PubMed ID: 17057757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavior of human apolipoprotein E in aqueous solutions and at interfaces.
    Yokoyama S; Kawai Y; Tajima S; Yamamoto A
    J Biol Chem; 1985 Dec; 260(30):16375-82. PubMed ID: 4066713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for a helical connector between two receptor binding sites of a long-chain peptide hormone.
    Beyermann M; Rothemund S; Heinrich N; Fechner K; Furkert J; Dathe M; Winter R; Krause E; Bienert M
    J Biol Chem; 2000 Feb; 275(8):5702-9. PubMed ID: 10681555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformation and lipid binding properties of four peptides derived from the membrane-binding domain of CTP:phosphocholine cytidylyltransferase.
    Johnson JE; Rao NM; Hui SW; Cornell RB
    Biochemistry; 1998 Jun; 37(26):9509-19. PubMed ID: 9649334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.
    Perrin MH; Tan LA; Vaughan JM; Lewis KA; Donaldson CJ; Miller C; Erchegyi J; Rivier JE; Sawchenko PE
    J Pharmacol Exp Ther; 2015 May; 353(2):307-17. PubMed ID: 25736419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of amphiphilic alpha-helical model peptides with systematically varied hydrophobic-hydrophilic balance and their interaction with lipid- and bio-membranes.
    Kiyota T; Lee S; Sugihara G
    Biochemistry; 1996 Oct; 35(40):13196-204. PubMed ID: 8855958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amunine (ovine CRF), urotensin I and sauvagine, three structurally-related peptides, produce selective dilation of the mesenteric circulation.
    MacCannell KL; Lederis K; Hamilton PL; Rivier J
    Pharmacology; 1982; 25(2):116-20. PubMed ID: 6982480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of end group blockage on the properties of a class A amphipathic helical peptide.
    Venkatachalapathi YV; Phillips MC; Epand RM; Epand RF; Tytler EM; Segrest JP; Anantharamaiah GM
    Proteins; 1993 Apr; 15(4):349-59. PubMed ID: 8460106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion of phospholipid vesicles induced by an amphiphilic model peptide: close correlation between fusogenicity and hydrophobicity of the peptide in an alpha-helix.
    Yoshimura T; Goto Y; Aimoto S
    Biochemistry; 1992 Jul; 31(26):6119-26. PubMed ID: 1627554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding.
    Gkountelias K; Tselios T; Venihaki M; Deraos G; Lazaridis I; Rassouli O; Gravanis A; Liapakis G
    Mol Pharmacol; 2009 Apr; 75(4):793-800. PubMed ID: 19124613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of the role of endothelium-dependent nitric oxide release in the sustained vasodilator effects of corticotrophin releasing factor and sauvagine.
    Barker DM; Corder R
    Br J Pharmacol; 1999 Jan; 126(1):317-25. PubMed ID: 10051151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticotropin-releasing factor type 1 and type 2alpha receptors regulate phosphorylation of calcium/cyclic adenosine 3',5'-monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase.
    Rossant CJ; Pinnock RD; Hughes J; Hall MD; McNulty S
    Endocrinology; 1999 Apr; 140(4):1525-36. PubMed ID: 10098484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.
    Beyermann M; Heinrich N; Fechner K; Furkert J; Zhang W; Kraetke O; Bienert M; Berger H
    Br J Pharmacol; 2007 Jul; 151(6):851-9. PubMed ID: 17533422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.